Indoor Tanning and Melanoma Risk: Molecular and Epidemiological Evidence
December 29, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Alucain( Pakistan), Fencaine (Taiwan), Magocain(Taiwan), Mezain (Taiwan), Neocane (Pakistan), Oxeway (Taiwan), Soothing (Taiwan), Sowecaine (Taiwan), Topicaine (Taiwan), Emoren (Italy)
Synonyms :
Oxetacaine, oxetacaina, oxetacain, oxetacainum, oxethazaine
Class :
Local anaesthetics
Brand Name :
Alucain( Pakistan), Fencaine (Taiwan), Magocain(Taiwan), Mezain (Taiwan), Neocane (Pakistan), Oxeway (Taiwan), Soothing (Taiwan), Sowecaine (Taiwan), Topicaine (Taiwan), Emoren (Italy)
Synonyms :
Oxetacaine, oxetacaina, oxetacain, oxetacainum, oxethazaine
Class :
Local anaesthetics
Dosage Forms & Strengths
Tablets
15mg
Granules
300mg
500mg
Oral suspension
Gastroesophageal Reflux Disease (GERD)
15mg to 40mg tablets orally once daily in 3–4 divided doses
(or)
15mg to 40mg granules orally once daily in 3–4 divided doses
(Or)
15-ml suspension orally once daily
Safety and efficacy study is not established
Refer to adult dosing
To be used with caution in elderly patients
may increase the risk or severity of methemoglobinemia when miltefosine is combined
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the rate of metabolism of alprazolam may be reduced
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the rate of metabolism of atorvastatin may be reduced
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia may be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia may be increased
Actions and spectrum:
By reducing the secretion of gastrin, oxetacaine prevents the secretion of gastric acid.
Additionally, the gastric mucosa is subjected to a local anesthetic effect by oxetacaine. Oxetacaine’s strong local anesthetic effect may be attributed to its distinct chemical properties, which include its weak base property and relative non-ionization in acidic solutions. At the same time, its hydrochloride salt exhibits solubility in organic solvents and cell membrane penetration.
The cell membrane permeability to sodium ions is decreased by oxetacaine through the reduction of sensory nerve impulse conduction in the vicinity of the application site. The unionized form is incorporated into the cell membrane to carry out this function.
Frequency not defined
Anorexia
Vertigo
Thirst
Sleepiness
Headache
Weakness
Rashes
Nausea
Black Box Warning
Not listed
Contraindication/Caution:
Contraindication:
Hypersensitivity
Pregnancy consideration:
USFDA pregnancy category: Safety studies are not established
Lactation:
Data about the excretion of oxetacaine into breast milk is not known
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Oxetacaine is a local anesthetic that acts as an antispasmodic and produces vasoprotective effects in combination with antacids
Pharmacodynamics:
By blocking or lessening the conduction of sensory nerve impulses close to the site of application, this amide-type local anesthetic causes a temporary loss of feeling. Additionally, this has the membrane-stabilizing effect of reducing the nerve cell membrane permeability to sodium ions. By raising the pH and neutralizing the gastric acid in the stomach, it relieves the symptoms of hyperacidity.
Pharmacokinetics:
Absorption
Peak plasma levels of about 20ng/ml are obtained in an hour after administering oxetacine orally.
Metabolism
It is metabolized extensively in the liver, with beta-hydroxy-mephentermine and beta-hydroxy-phentermine being the primary metabolites.
Elimination and excretion
About 0.1% of administered oxetacaine is eliminated through urine as its metabolite or unchanged form.
Half-life:
One hour
Administration:
Administer oxetacine orally before food
Patient information leaflet
Generic Name: oxetacaine
Why do we use oxetacaine?
Oxetacaine is an amide-type local anesthetic used to treat heartburn, peptic ulcers, anorexia, gastritis, and hiatus hernia. It is also used in combination with other antacids to treat acid reflux, hemorrhoids, anal eczema, proctitis, etc.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
